# C-Bridge Capital

> C-Bridge Capital is a VC fund backing Biotechnology and Health Care. See 20 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 20
- Last investment: Jul 2026
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/c-bridge-capital/about/
- Website: http://www.cbridgecap.com/

C-Bridge Capital is a VC fund in New York focused on Biotechnology and Health Care. C-Bridge Capital Partners identifies and unlocks opportunities to drive growth and development across borders. They leverage their expertise in the United States, China and Israel to help their global clients form international strategic alliances that achieve maximum returns. Using their unparalleled network and extensive knowledge, Theyfacilitate cross-border investments and asset formation in the US, China and Israel. They remain involved to monitor and protect their clients’ investment interests.

## Contacts

5 contacts available for C-Bridge Capital. Shizune tracks 6 team members at C-Bridge Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/c-bridge-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 10 | 50% |
| Health Care | 6 | 30% |
| Medical | 4 | 20% |
| Pharmaceutical | 4 | 20% |
| Biopharma | 3 | 15% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 20% |
| Series A | 3 | 15% |
| Series C | 3 | 15% |
| Debt Financing | 3 | 15% |
| Angel | 1 | 5% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 8 | 40% |
| United States | 5 | 25% |
| Singapore | 1 | 5% |
| United Arab Emirates | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Wei Fu | Founder & Chief Executive Officer | 7 | https://shizune.co/investors/profile/wei-fu |
| Abbas Hussain | Senior Partner | 0 | https://shizune.co/investors/profile/abbas-hussain |
| Christopher Shen | Managing Director | 2 | https://shizune.co/investors/profile/christopher-shen |
| Kang Lan | Managing Director | 0 | https://shizune.co/investors/profile/kang-lan |
| Lu Yanxiang | Senior Managing Director | 2 | https://shizune.co/investors/profile/lu-yanxiang |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Hailong Aerospace | Hailong Aerospace is a technological business that specializes in system solutions and high-precision attitude control components for commercial satellites. Hailong Aerospace specializes in high-precision satellite attitude control systems, specifically the "steering wheel" and "stabilizer" of commercial aircraft. |  | Angel | Jul 09, 2026 |  |
| EverBridge | Ruiqiao Dingke Group is a medical technology group . Adhering to the core concept of "fast and high-quality scale", it gives full play to the advantages of platformization and accurately captures global industry trends and market demands. | $137.8M | Series A | Mar 25, 2025 |  |
| Human Investments | Human Investments is the exclusive distribution partner in Korea and China for Establishment Labs Holdings. Through its subsidiaries Motiva Korea and Motiva China, Human Investments Ltd. currently markets Motiva® devices in the Korea and China markets. Motiva® Devices, known for their advanced 3D negative imprinting technology, are recognized fortheir superior safety and natural look and feel. | $50M | Debt Financing | Dec 10, 2024 |  |
| Synaptic Medical | Synaptic Medical is a medical device company focused on developing and commercializing breakthrough products for the treatment of cardiac arrhythmias and other cardiovascular diseases. Their mission is to develop unique, cost-effective, and clinically advanced technologies with the highest quality to enable physicians to optimize and expandtreatment options. The company was founded in 2005 in Minnesota. | $40M | Debt Financing | Nov 28, 2024 |  |
| Hasten | Hasten is a pharmaceutical manufacturing company that integrates R&D, manufacturing, and commercialization, and covers the entire industry chain. They are dedicated to creating China's innovative medical and health company, and they collaborate with key government agencies, medical and health professionals, and industry partners to providehigh-quality solutions, build a health management ecosystem, and benefit more patients. | $315M | Venture - Series Unknown | Apr 20, 2023 |  |
| RVAC Medicines | RVAC Medicines is a mRNA platform company engaged in the research and development of innovative products such as vaccines for diseases. | $140M | Series B | Apr 26, 2022 |  |
| RVAC Medicines | RVAC Medicines is a mRNA platform company engaged in the research and development of innovative products such as vaccines for diseases. | $140M | Series B | Apr 26, 2022 |  |
| LakeShore Biopharma | Yisheng Biopharma is a global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using our novel PIKA® immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine and the PIKA rabies vaccine for accelerated protection against rabies infection. | $40M | Debt Financing | Mar 23, 2022 |  |
| NiKang Therapeutics | NiKang Therapeutics is an early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Its discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development ofproprietary drug candidates with the most desirable pharmacological features into clinical studies. | $200M | Series C | May 26, 2021 |  |
| Adcentrx Therapeutics | Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies forimproving patient treatment options. | $50M | Series A | Apr 28, 2021 |  |

10 of 20 investments shown.

## Co-investors
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund, 4 deals together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 3 deals together
- [Pavilion Capital](https://shizune.co/investors/profile/pavilion-capital) — VC Fund, 3 deals together
- [CDH Investments](https://shizune.co/investors/profile/cdh-investments) — VC Fund, 2 deals together
- [GS Holdings](https://shizune.co/investors/profile/gs-holdings) — VC Fund, 2 deals together
- [HBM Healthcare Investments](https://shizune.co/investors/profile/hbm-healthcare-investments-ag) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does C-Bridge Capital invest in?

C-Bridge Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 20 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact C-Bridge Capital?

Public channels for C-Bridge Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at C-Bridge Capital?

The team at C-Bridge Capital includes Wei Fu (Founder & Chief Executive Officer), Abbas Hussain (Senior Partner) and Christopher Shen (Managing Director), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co